Enfuvirtide and cutaneous injection-site reactions.
J Drugs Dermatol
; 11(10): e35-8, 2012 Oct.
Article
en En
| MEDLINE
| ID: mdl-23134996
ABSTRACT
Enfuvirtide belongs to a newer class of antiretroviral (ARV) agents called fusion inhibitors for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Enfuvirtide blocks attachment, binding, and entry of the viral capsid into the host CD4+ cell. Administration is only available subcutaneously in a twice-daily regimen particularly for those patients who have previously failed more than one ARV regimen. Common side effects of enfuvirtide administration include fatigue, insomnia, nausea, and diarrhea; however, injection-site reactions are the most common side effect and present in nearly all individuals undergoing treatment. The spectrum of cutaneous manifestations ranges from little to no reaction to cysts, nodules, induration, or sclerodermalike lesions. These reactions are mostly variants of iatrogenically induced hypersensitivity and are self-limited.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Fragmentos de Péptidos
/
Proteína gp41 de Envoltorio del VIH
/
Infecciones por VIH
/
VIH-1
/
Erupciones por Medicamentos
/
Inhibidores de Fusión de VIH
/
Quiste Epidérmico
Tipo de estudio:
Etiology_studies
Límite:
Humans
Idioma:
En
Año:
2012
Tipo del documento:
Article